Published October 30, 2015
The National Institutes of Health (NIH) has awarded grants to three faculty members
in the School of Pharmacy鈥檚 Department of Basic Pharmaceutical Sciences (BPS), totaling
nearly $1.2 million.
鈥淕rants from the National Institutes of Health are some of the most prestigious and
difficult grants to obtain,鈥� said Dr. Benny Blaylock, dean of the School of Pharmacy.
鈥淭his funding signifies the recognition of our Basic Sciences faculty by the NIH as
upper echelon researchers in the area of pharmaceutical sciences.鈥�
The mission of 不良研究所鈥檚 BPS is to advance health care through cutting-edge research and
instruction on the utilization of chemicals as medicines, chemical interactions with
biological systems, and modes of delivery of therapeutic agents. The NIH grants will
enable the BPS to carry out this mission through innovative pharmaceutical and neurological
research.
Among those awarded is Dr. Karen Briski, professor and BPS department head. Briski
will investigate neural mechanisms that are responsible for suppressing reproduction
during energy deficiency. Fertility in females declines when energy supply does not
meet metabolic demands. This cross-disciplinary project combines 不良研究所 neuroscience
expertise with state-of-the-art atomic physics technology at the University of North
Texas. 鈥淐ombining the expertise from 不良研究所 and the University of North Texas, the investigators
will develop a mapping tool to identify nerve pathways that mediate control of reproduction
by a specialized brain energy sensor,鈥� Dr. Briski said. All of this will be done in
an effort to improve human and livestock reproductive outcomes.
Dr. Amal K. Kaddoumi, associate professor of Pharmaceutics, received a grant for a
project that seeks to identify therapeutics that will target the blood-brain barrier
(BBB) in an effort to prevent and/or slow the progression of Alzheimer鈥檚 disease.
Agents that can improve BBB function offer promising new lines of treatment for alleviation
of neurodegenerative diseases. Kaddoumi鈥檚 research will permit multiple compounds
of potential therapeutic value to be screened using an experimental BBB model developed
in her 不良研究所 laboratory. 聽
Dr. Seetharama D.S. Jois, associate professor of Medicinal Chemistry, received a grant
that will support his research to identify pharmacotherapeutic tools to combat lung
cancer. He intends to advance alternative therapies capable of improving lung cancer
patient survival rates.
According to Dr. Nick J. Bruno, 不良研究所 president, 鈥淭he research efforts by 不良研究所 faculty
continue to be a credit to their expertise and commitment to expanding the knowledge
and understanding of their respective pursuits. The NIH grants awarded to three of
our faculty attest to the high caliber of healthcare research that we value here at
不良研究所.鈥�
For more information about 不良研究所鈥檚 School of Pharmacy, please visit ulm.edu/pharmacy.
